Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Iptacopan in Hepatic Impairment
NCT05078580Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), Complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN) (4 arms), sponsored by Novartis. Primary endpoints: Maximum observed plasma concentration, Time to maximum concentration and 2 more. Started Nov 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)Complement 3 glomerulopathy (C3G)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05078580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078580.